Artificial nerves approved for manufacturing and sales by the US FDA. Developed by Dr. Suzuki, who is affiliated with our hospital, for 25 years.

This was developed by Dr. Suzuki, who is currently practicing medicine at our hospital, at the Kyoto University School of Medicine about 25 years ago.(Yoshihisa Suzuki – My portal – researchmap)The artificial nerve using alginate, which has already been patented in major countries, has now received manufacturing and sales approval from the US FDA (Food and Drug Administration). It will initially be sold in the US under the trademark "ReFeel." It is planned to be used for treating sensory paralysis caused by peripheral nerve damage due to injury, and urinary problems and erectile dysfunction caused by pelvic nerve damage after surgery for uterine or prostate cancer.

Mochida Pharmaceutical [4534]: Notice of obtaining 510(k) clearance in the United States for the nerve regeneration inducer "ReFeel" July 2, 2024 (timely disclosure) : Nikkei Company Information DIGITAL: Nikkei Newspaper